Geuguer-Chávez L, Pedro- González A, López-Véjar CE, Elizalde-Barrera CI, Guerrero- González J

Language: Spanish
References: 21
Page: 11-23
PDF size: 1132.68 Kb.

ABSTRACT

Background: Alcoholic hepatitis is one of the major health problems in Mexico, its mortality is 30%-60% in the severe form. The gamma glutamyl transpeptidase (GGT) is a sensitive parameter of liver disease induced by alcohol. The above data suggest that serum GGT can be an indicator of healthy liver tissue.
Objective: To determine whether there is an association between serum GGT with hospital mortality in patients with severe alcoholic hepatitis.
Material and method: An observational, analytic, cohort study included 48 patients in total with diagnosis of severe alcoholic hepatitis, 24 patients with higher than 300 U/L and 24 patients with lower than 300 U/L. Serum GGT and total bilirubin levels were measured at admission and at 28 days. Registering developing of hepatic encephalopathy, acute renal failure, infections, upper gastrointestinal bleeding and documenting the days of hospital stay (DHS) as well as number of deaths attributed to the alcoholic hepatitis presented in each group.
Results: The association of GGT with mortality in patients with severe alcoholic hepatitis using χ² was 2,087 with a value of p = 0.149, RR was 0.643 with CI 95% from 0.135 to 1.365. For hepatic encephalopathy, χ² was 4.463 with a p ‹0.05, the RR was 0.632 with CI 95% from 0.403 to 0.99. For acute renal failure the χ² was 7.056 with a p ‹0.05, the RR was 0.357, with CI 95% in 0.153 to 0836. The χ² for upper gastrointestinal bleeding was 2.009 with a p › 0.05 and a RR of 4.000, with 95% CI 0.482 to 33.22. The infectious processes resulted in a χ² of 4,364, with a p ‹0.05. The treatment response obtained a χ² of 0.99, with a p value = 0.32, with a RR of 0.587 with CI 95% in 0.203 to 1.693.
Conclusions: The elevated serum GGT was not associated to lower mortality in patients with severe alcoholic hepatitis; however, it showed to be a protective factor against complications such as hepatic encephalopathy, acute renal failure and infections, but not against upper gastrointestinal bleeding. There was no association between serum GGT levels and the number of days of hospital stay, response to treatment and bilirubin total levels at admission and 28 days after.

REFERENCES

1. Lucey MR, Mathurin P, Morgan TR. Alcoholic hepatitis. N Eng J Med 2009;360:2758-69.

2. Méndez Sánchez N, Almeda Valdés P, Uribe M. Alcoholic liver disease. An update. Ann Hepatology 2005;4:32-42.

3. Gramenzi A, Caputo F, Biselli M, Kuria F, et al. Alcoholic liver disease – Pathophysiological aspects and risk factors. Aliment Pharmacol Ther 2006;24:1151-1161.

4. Secretaría de Salud, Subsecretaría de Planeación, Dirección General de Estadística e Informática. Mortalidad 1995. Principales causas de mortalidad general. México: SSA, 1995;69.

5. Sass DA, Shaikh OS. Alcoholic hepatitis. Clin Liver Dis 2006;10:219-237.

6. Higuera-de la Tijera MF, Pérez-Hernández JL, Servín- Caamaño AI, et al. Hepatitis alcohólica. Rev Med Hosp Gen Mex 2009;72:215-221.

7. Basra S, Anand BS. Definition, epidemiology and magnitude of alcoholic hepatitis. World J Hepatol 2011;3:108-113.

8. Cuadrado A, Crespo J. Hypertransaminasemia in patients with negative viral markers. Rev Esp Enferm Dig 2004; 96:484-500.

9. Bellini M, Tumino E, Giordan R, et al. Serum Y-glutamyltranspeptidase isoforms in alcoholic liver disease. Alcohol & Alcoholism 1997; 32:259-266.

10. Haber PS, Warner R, Seth D, et al, Pathogenesis and management of alcoholic hepatitis, review. J Gastroenterol Hepatol 2003;18:1332-1344.

11. Amini M, Runyon BA. Alcoholic hepatitis 2010: A clinician’s guide to diagnosis and therapy. World J Gastroenterol 2010;16:4905-4912.

12. Hietala J, Koivisto H, Anttila P, et al. Comparison of the combined marker Ggt–Cdt and the conventional laboratory markers of alcohol abuse in heavy drinkers, moderate drinkers and abstainers. Alcohol & Alcoholism 2006;41:528-533.

13. Giannini EG, Testa R, Savarino V. Liver enzyme alteration: a guide for clinicians. CMAJ 2005;172.

14. Haren MT, Li M, Petkov J, et al. Alcohol, metabolic risk and elevated serum gamma-glutamyl transferase (GGT) in Indigenous Australians. BMC Public Health 2010;10:454.

15. Guo-Qing H, Cheng-Yong Q, Rong-Hua S. The analysis of gglutamyl transpeptidase gene in different type liver tissues. World J Gastroenterol 2003;9:276-280.

16. Chen J, Conigrave KM, Macaskill P, et al. Combining carbohydrate-deficient transferrin and gamma-glutamyltransferase to increase diagnostic accuracy for problem drinking. Alcohol & Alcoholism 2003;38:574-582.

17. Laatikainen T, Alho H, Vartiainen E, et al. Self-reported alcohol consumption and association to carbohydratedeficient transferrin and gamma-glutamyltransferase in a random sample of the general population in the Republic of Karelia, Russia and in North Karelia, Finland. Alcohol Alcoholism 2002;37:282-288.

18. Chao-Hui Y, Cheng-Fu X, Hua Y, et al. Early mortality of alcoholic hepatitis: A review of data from placebo- controlled clinical trials. World J Gastroenterol 2010;16:2435-2439.

19. O’Shea RS, McCullough AJ. Treatment of alcoholic hepatitis. Clin Liver Dis 2005;9:103-134.

20. Wakim-Fleming J, Mullen KD. Long-term management of alcoholic liver disease. Clin Liver Dis 2005;9:135-149.

21. Argimón J, Jiménez J. Métodos de investigación. Madrid: Ediciones Harcourt, 2000.